Medtronic announces fda approval of next-gen tavr system for treatment of symptomatic severe aortic stenosis

Dublin, aug. 24, 2021 /prnewswire/ -- medtronic plc (nyse: mdt), the global leader in medical technology, today announced u.s. food and drug administration (fda) approval of its newest-generation, self-expanding transcatheter aortic valve replacement (tavr) system, the evolut™ fx tavr system. designed to enhance ease-of-use and provide greater precision and control throughout the procedure, the evolut fx system maintains the industry-leading hemodynamic (blood flow) and durability benefits of the evolut platform, while bringing product and procedure innovation for patients with symptomatic severe aortic stenosis.
MDT Ratings Summary
MDT Quant Ranking